Authors’ Reply to the Letter to the Editor by Daniel M. Green

Authors:
Jeffrey S. Dome Center for Cancer and Blood Disorders, Children’s National Hospital, and George Washington University School of Medicine and Health Sciences, Washington, DC

Search for other papers by Jeffrey S. Dome in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Elizabeth A. Mullen
Search for other papers by Elizabeth A. Mullen in
Current site
Google Scholar
PubMed
Close
 MD
,
David B. Dix
Search for other papers by David B. Dix in
Current site
Google Scholar
PubMed
Close
 MD
,
Eric J. Gratias
Search for other papers by Eric J. Gratias in
Current site
Google Scholar
PubMed
Close
 MD
,
Peter F. Ehrlich
Search for other papers by Peter F. Ehrlich in
Current site
Google Scholar
PubMed
Close
 MD
,
Najat C. Daw
Search for other papers by Najat C. Daw in
Current site
Google Scholar
PubMed
Close
 MD
,
James I. Geller
Search for other papers by James I. Geller in
Current site
Google Scholar
PubMed
Close
 MD
,
Murali Chintagumpala
Search for other papers by Murali Chintagumpala in
Current site
Google Scholar
PubMed
Close
 MD
,
Geetika Khanna
Search for other papers by Geetika Khanna in
Current site
Google Scholar
PubMed
Close
 MD
,
John A. Kalapurakal
Search for other papers by John A. Kalapurakal in
Current site
Google Scholar
PubMed
Close
 MD
,
Lindsay Renfro
Search for other papers by Lindsay Renfro in
Current site
Google Scholar
PubMed
Close
 PhD
,
Elizabeth J. Perlman
Search for other papers by Elizabeth J. Perlman in
Current site
Google Scholar
PubMed
Close
 MD
,
Paul E. Grundy
Search for other papers by Paul E. Grundy in
Current site
Google Scholar
PubMed
Close
 MD
, and
Conrad V. Fernandez
Search for other papers by Conrad V. Fernandez in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access
  • Collapse
  • Expand
  • 1.

    Dome JS, Mullen EA, Dix DB, et al. Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw 2021;19:978985.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Green DM. Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor. J Clin Oncol 2020;38:772773.

  • 3.

    Green DM. Treatment of stage IV favorable histology Wilms tumor with lung metastases [published online September 13, 2018]. J Clin Oncol, doi: 10.1200/JCO.18.00101

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Dix DB, Fernandez CV, Chi YY, et al. Reply to D.M. Green. J Clin Oncol 2020;38:773774.

  • 5.

    Dix DB, Seibel NL, Chi YY, et al. Reply to D.M. Green [published online September 13, 2018]. J Clin Oncol, doi: 10.1200/JCO.18.00659

  • 6.

    Dix DB, Seibel NL, Chi YY, et al. Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol 2018;36:15641570.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Grundy PE, Green DM, Dirks AC, et al. Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012;59:631635.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Dix DB, Fernandez CV, Chi YY, et al. Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol 2019;37:27692777.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007;48:493499.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008;50:236241.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Mullen EA, Chi YY, Hibbitts E, et al. Impact of surveillance imaging modality on survival after recurrence in patients with favorable-histology Wilms tumor: a report from the Children’s Oncology Group [published online October 18, 2020]. J Clin Oncol, doi: 10.1200/JCO.18.00076

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 22332 260 20
PDF Downloads 302 74 7
EPUB Downloads 0 0 0